{"id":497880,"date":"2020-07-22T19:10:02","date_gmt":"2020-07-22T19:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497880"},"modified":"2020-07-22T19:10:02","modified_gmt":"2020-07-22T19:10:02","slug":"vernal-keratoconjunctivitis-epidemiology-analysis-historical-trends-and-forecast-201730","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-epidemiology-analysis-historical-trends-and-forecast-201730_497880.html","title":{"rendered":"Vernal Keratoconjunctivitis Epidemiology Analysis, Historical Trends and Forecast 2017-30"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1595411764.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Vernal Keratoconjunctivitis Epidemiology Analysis, Historical Trends and Forecast 2017-30\" src=\"https:\/\/www.abnewswire.com\/uploads\/1595411764.jpeg\" alt=\"Vernal Keratoconjunctivitis Epidemiology Analysis, Historical Trends and Forecast 2017-30\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Vernal Keratoconjunctivitis Epidemiology Forecast<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Vernal keratoconjunctivitis prevalence in the studied geographies was estimated to be 4,752,356 in 2017, and the VKC prevalence is further expected to rise. China accounted for the maximum Vernal keratoconjunctivitis prevalent cases in 2017 with 2,248,706 cases.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-epidemiology-forecast\">&#8216;Vernal Keratoconjunctivitis &#8211; Epidemiology Forecast to 2030<\/a><\/strong>&#8216; report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the major as well as emerging markets.<\/p>\n<p style=\"text-align: justify;\"><strong>Geographies Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The United States<\/li>\n<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/li>\n<li>Japan<\/li>\n<li>MEA (Saudi Arabia, Egypt, UAE)<\/li>\n<li>China<\/li>\n<li>Russia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Study Period<\/strong>: 2017-2030<\/p>\n<p style=\"text-align: justify;\"><strong>Vernal keratoconjunctivitis<\/strong> (VKC) is a bilateral, seasonally recurring, allergic inflammation of the conjunctiva. It gives rise to several complications of ocular surface and cornea, causing corneal scars and keratoconus. If left untreated, it results in vision loss.<\/p>\n<p style=\"text-align: justify;\">It is an IgE-mediated and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: <strong>palpebral, bulbar, <\/strong>and<strong> mixed form<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Know more about report offerings: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-epidemiology-forecast\">https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-epidemiology-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Vernal keratoconjunctivitis Epidemiology <\/strong><\/p>\n<p style=\"text-align: justify;\">Vernal keratoconjunctivitis generally affects younger boys and often appears during warmer climates, however, gets resolved after puberty. VKC Epidemiological analysis demonstrated that the conditions run in the family, and the VKC patients have a family history of the related allergic disorder. The condition is prevalent in hot and dry regions in Sub-Saharan Africa, Central and South America, the Mediterranean basin, Middle East regions and Asian regions.<\/p>\n<p style=\"text-align: justify;\">The Vernal keratoconjunctivitis prevalence in the studied geographies was estimated to be <strong>4,752,356<\/strong> in 2017, and the VKC prevalence is further expected to rise.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><strong>China accounted for the maximum Vernal keratoconjunctivitis prevalent cases in 2017 with 2,248,706 cases.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><strong>Read more:&nbsp;<\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/vernal-keratoconjunctivitis-vkc-market\/\">https:\/\/www.delveinsight.com\/blog\/vernal-keratoconjunctivitis-vkc-market\/<\/a><\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/e15924d46cb25e429d7688dd0b522326.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">The Vernal keratoconjunctivitis epidemiology covered in the report provides historical as well as forecasted epidemiology segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Vernal keratoconjunctivitis Prevalent Population<\/li>\n<li>Diagnosed Vernal keratoconjunctivitis Prevalent Population<\/li>\n<li>Gender-specific Diagnosed Vernal keratoconjunctivitis Prevalent Population<\/li>\n<li>Type-specific Diagnosed Vernal keratoconjunctivitis Prevalent Population<\/li>\n<li>Severity-specific Diagnosed Vernal keratoconjunctivitis Prevalent Population, and<\/li>\n<li>Age-specific Diagnosed Vernal keratoconjunctivitis Prevalent Population<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample pages: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-epidemiology-forecast\">https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-epidemiology-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Vernal Keratoconjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Vernal Keratoconjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Vernal Keratoconjunctivitis in geographies studied<\/li>\n<li>The report provides insight into the historical, and the forecasted patient pool of Vernal Keratoconjunctivitis in geographies studied<\/li>\n<li>The report helps to recognize the growth opportunities in the geographies analyzed with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Vernal Keratoconjunctivitis<\/li>\n<li>The report provides the segmentation of the Vernal Keratoconjunctivitis epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Vernal keratoconjunctivitis (VKC)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Vernal keratoconjunctivitis Epidemiology Overview at a Glance<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Disease Background and Overview: Vernal keratoconjunctivitis <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5. Vernal keratoconjunctivitis Case Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6. Vernal keratoconjunctivitis Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. United States Vernal keratoconjunctivitis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. EU5 Vernal keratoconjunctivitis Epidemiology<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Germany Epidemiology<\/strong><\/li>\n<li><strong>France Epidemiology<\/strong><\/li>\n<li><strong>Italy Epidemiology<\/strong><\/li>\n<li><strong>Spain Epidemiology<\/strong><\/li>\n<li><strong>United Kingdom Epidemiology<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>9. Japan Vernal keratoconjunctivitis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. MEA Vernal keratoconjunctivitis Region Epidemiology<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Saudi Arabia Epidemiology<\/strong><\/li>\n<li><strong>Egypt Epidemiology<\/strong><\/li>\n<li><strong>UAE Epidemiology<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>11. China Vernal keratoconjunctivitis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Russia Vernal keratoconjunctivitis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>14. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors<\/p>\n<p style=\"text-align: justify;\"><strong>Browse through our vast repository: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store.php\">https:\/\/www.delveinsight.com\/report-store.php<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57049.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Vinita Rakheja <br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=vernal-keratoconjunctivitis-epidemiology-analysis-historical-trends-and-forecast-201730\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=vernal-keratoconjunctivitis-epidemiology-analysis-historical-trends-and-forecast-201730\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vernal Keratoconjunctivitis Epidemiology Forecast The Vernal keratoconjunctivitis prevalence in the studied geographies was estimated to be 4,752,356 in 2017, and the VKC prevalence is further expected to rise. China accounted for the maximum Vernal keratoconjunctivitis prevalent cases in 2017 with &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-epidemiology-analysis-historical-trends-and-forecast-201730_497880.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413,404,416],"tags":[],"class_list":["post-497880","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497880"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497880\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}